Table 3. Medications used in patients with cystic fibrosis.
Data are presented as numbers (%).
aFisher’s exact test
P-value < 0.05 is considered statistically significant.
Bold values indicate statistical significance.
*These vitamins were stopped at least three days before enrollment in the study.
ADEK: fat-soluble vitamins A, D, E, and K
| Medication used | Vitamin E Level | P-valuea | Total, n = 35 (100) | |
| Low, n = 9 (25.7) | Normal, n = 26 (74.3) | |||
| Pancreatic enzyme replacement therapy | 8 (88.9) | 24 (92.3) | 1.000 | 32 (91.4) |
| Previous ADEK supplementation* | 6 (66.7) | 24 (92.3) | 0.095 | 30 (85.7) |
| Bronchodilator (salbutamol) | 1 (11.1) | 15 (57.7) | 0.022 | 16 (45.7) |
| Dornase alfa | 4 (44.4) | 10 (38.5) | 1.000 | 14 (40.0) |
| Oral antibiotic (azithromycin) | 4 (44.4) | 8 (30.8) | 0.685 | 12 (34.3) |
| Multivitamins | 2 (22.2) | 8 (30.8) | 1.000 | 10 (28.6) |
| Inhaled antibiotic (tobramycin) | 2 (22.2) | 8 (30.8) | 1.000 | 10 (28.6) |
| Proton pump inhibitor | 2 (22.2) | 3 (11.5) | 0.586 | 5 (14.3) |
| Inhaled steroid | 0 (0.0) | 5 (19.2) | 0.297 | 5 (14.3) |
| Ursodeoxycholic acid | 2 (22.2) | 2 (7.7) | 0.268 | 4 (11.4) |
| Vitamin D supplementation | 2 (22.2) | 2 (7.7) | 0.268 | 4 (11.4) |
| Iron supplementation | 0 (0.0) | 1 (3.8) | 1.000 | 1 (2.9) |